⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCYX News
SCYNEXIS, Inc.
Form 8-K
sec.gov
SCYX
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
businesswire.com
SCYX
Poxel annonce la cession du PXL770 à la société Scynexis pour un montant total pouvant atteindre jusqu’à 196 millions de dollars
businesswire.com
SCYX
Form 8-K
sec.gov
SCYX
Form 8-K
sec.gov
SCYX
SCYNEXIS Announces $40.0 Million Private Placement
globenewswire.com
SCYX
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
globenewswire.com
SCYX
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
SCYX
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
globenewswire.com
SCYX
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
globenewswire.com
SCYX
CRVO